Compare CCEL & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEL | CVRX |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 37.8M |
| IPO Year | 2022 | 2021 |
| Metric | CCEL | CVRX |
|---|---|---|
| Price | $5.05 | $1.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.58 |
| AVG Volume (30 Days) | 11.2K | ★ 408.2K |
| Earning Date | 10-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ 0.23 | N/A |
| Revenue | $25,384,279.00 | ★ $56,651,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | N/A | $12.45 |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | 9.76 | ★ 10.45 |
| 52 Week Low | $2.72 | $1.26 |
| 52 Week High | $5.45 | $10.28 |
| Indicator | CCEL | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 45.23 |
| Support Level | $3.14 | $1.50 |
| Resistance Level | N/A | $3.19 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 77.74 | 94.20 |
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.